The Globe and Mail reports in its Tuesday, Oct. 1, edition that Leede Financial analyst Douglas Loe commenced coverage on Medexus Pharmaceuticals with a "speculative buy" ranking and a Street-high share target of $8.25. The Globe's David Leeder writes that analysts on average target the shares at $3.30. Mr. Loe says in a note: "It is unusual for us to ascribe a 'speculative' rating to a positive cash flow-generating firm, but we believe our rating is justified in this circumstance with much of achievable market value we are projecting embedded into a single soon-to-be-regulatory-stage oncology asset, the alkylating agent Treosulfan. We expect FDA review of a resubmitted new drug application (NDA) filing to conclude by early FQ425. Germany-based specialty pharmaceutical partner medac GmbH (private) submitted the revised NDA in Apr/24, and the filing was formally accepted by the U.S." The Globe reported on Aug. 23 that Stifel analyst Justin Keywood had reiterated his "buy" recommendation for Medexus Pharmaceuticals. In the item, Mr. Keywood said, "We believe Medexus's valuation has fallen too far at only four times expected EBITDA and highlights a solid risk-to-reward setup." It was then worth $2.41.